Overview

Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2016-08-04
Target enrollment:
Participant gender:
Summary
RATIONALE: Vatalanib and pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vatalanib may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving vatalanib together with pemetrexed disodium may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vatalanib when given together with pemetrexed disodium in treating patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
National Cancer Institute (NCI)
Treatments:
Pemetrexed
Vatalanib